Analysen von Matthew Weston
| 29.04.25 | Novartis Neutral | UBS AG | |
| 29.04.25 | AstraZeneca Buy | UBS AG | |
| 25.04.25 | Merck Buy | UBS AG | |
| 25.04.25 | Roche Buy | UBS AG | |
| 24.04.25 | Roche Buy | UBS AG | |
| 17.04.25 | Sartorius vz. Neutral | UBS AG | |
| 16.04.25 | Sartorius vz. Neutral | UBS AG | |
| 14.04.25 | Roche Buy | UBS AG | |
|
Werbung
|
|||
| 10.04.25 | Novartis Neutral | UBS AG | |
| 10.04.25 | AstraZeneca Buy | UBS AG | |
| 09.04.25 | Novartis Neutral | UBS AG | |
| 07.04.25 | Roche Buy | UBS AG | |
| 01.04.25 | AstraZeneca Buy | UBS AG | |
| 17.03.25 | AstraZeneca Buy | UBS AG | |
| 12.03.25 | Roche Buy | UBS AG | |
| 12.03.25 | AstraZeneca Buy | UBS AG | |
| 12.03.25 | Merck Buy | UBS AG | |
| 10.03.25 | AstraZeneca Buy | UBS AG | |
| 10.03.25 | AstraZeneca Buy | UBS AG | |
| 07.03.25 | Merck Buy | UBS AG | |
| 06.03.25 | Merck Buy | UBS AG | |
| 27.02.25 | Merck Buy | UBS AG | |
| 21.02.25 | Roche Buy | UBS AG | |
| 13.02.25 | Novartis Neutral | UBS AG | |
| 13.02.25 | AstraZeneca Buy | UBS AG | |
| 06.02.25 | AstraZeneca Neutral | UBS AG | |
| 03.02.25 | Novartis Buy | UBS AG | |
| 31.01.25 | Novartis Buy | UBS AG | |
| 31.01.25 | Roche Neutral | UBS AG | |
| 30.01.25 | AstraZeneca Neutral | UBS AG | |
| 30.01.25 | Roche Neutral | UBS AG | |
| 29.01.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 29.01.25 | Sartorius vz. Neutral | UBS AG | |
| 28.01.25 | Sartorius vz. Neutral | UBS AG | |
| 28.01.25 | Roche Neutral | UBS AG | |
| 27.01.25 | Novartis Buy | UBS AG | |
| 24.01.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 23.01.25 | Sartorius vz. Neutral | UBS AG | |
| 21.11.24 | Novartis Buy | UBS AG | |
| 20.11.24 | AstraZeneca Neutral | UBS AG | |
| 15.11.24 | Merck Buy | UBS AG | |
| 14.11.24 | Novartis Buy | UBS AG | |
| 14.11.24 | Merck Buy | UBS AG | |
| 13.11.24 | Roche Neutral | UBS AG | |
| 12.11.24 | AstraZeneca Sell | UBS AG | |
| 07.11.24 | AstraZeneca Sell | UBS AG | |
| 05.11.24 | AstraZeneca Sell | UBS AG | |
| 05.11.24 | AstraZeneca Sell | UBS AG | |
| 30.10.24 | Roche Neutral | UBS AG | |
| 30.10.24 | Novartis Buy | UBS AG | |